ArticleJournal of neuro-oncology2012
Salvage treatment with temozolomide in refractory or relapsed primary central nervous system lymphoma and assessment of the MGMT status.
Article in Journal of neuro-oncology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 40 citations in OpenAlex.
- O6-methylguanine-DNA methyltransferase (MGMT) immunohistochemistry as a predictor of resistance to temozolomide in primary CNS lymphoma.Journal of neuro-oncology · 2013Trial
- Multicenter phase II study of rituximab and temozolomide in recurrent primary central nervous system lymphoma.Leukemia & lymphoma · 2013Trial
- Efficacy of individualized orelabrutinib-based regimens in relapsed or refractory central nervous system lymphoma.Frontiers in neurology · 2025Article
- Recent advances and challenges in primary central nervous system lymphoma: a narrative review.Translational cancer research · 2023Review
- Efficacy and toxicity with radiation field designs and concurrent temozolomide for CNS lymphoma.Neuro-oncology practice · 2022Article
- Central Nervous System Lymphoma: Novel Therapies.Current treatment options in oncology · 2022Review
- Relapsed and refractory primary CNS lymphoma: treatment approaches in routine practice.Annals of lymphoma · 2021Article
- Relapsed Primary Central Nervous System Lymphoma: Current Advances.Frontiers in oncology · 2021Review
- Chemoradiotherapy with temozolomide after high-dose methotrexate for primary CNS lymphoma: a multicenter phase I study of a response-adapted strategy.Annals of hematology · 2020Article
- Systemic Approach to Recurrent Primary CNS Lymphoma: Perspective on Current and Emerging Treatment Strategies.OncoTargets and therapy · 2020Review
- Primary Central Nervous System Lymphoma: Molecular Pathogenesis and Advances in Treatment.Translational oncology · 2019Review
- Primary CNS Lymphoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2017Review
- Primary diffuse large B-cell lymphoma of the central nervous system: A case report and literature review.Oncology letters · 2016Article
- Efficacy of Procarbazine, Lomustine, and Vincristine Chemotherapy for Recurrent Primary Central Nervous System Lymphomas.Brain tumor research and treatment · 2015Article
- Prognostic impact of completion of initial high-dose methotrexate therapy on primary central nervous system lymphoma: a single institution experience.International journal of clinical oncology · 2015Article
- High-dose methotrexate plus temozolomide as a salvage treatment in metastatic central nervous system Lymphoma: two cases report and review of literature.International journal of clinical and experimental medicine · 2015Article
- Primary CNS lymphoma.Current hematologic malignancy reports · 2014Review
- Methotrexate re-challenge for recurrent primary central nervous system lymphoma.Journal of neuro-oncology · 2014Article
- Treatment of primary CNS lymphoma.Current treatment options in neurology · 2014Article
- Recent advances in treatment of primary central nervous system lymphoma.Current treatment options in oncology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
High-dose methotrexate (HD-MTX) is effective in the initial treatment of primary central nervous system lymphoma (PCNSL). Because treatment options in patients with progressive or recurrent PCNSL are limited, prognosis is poor. Temozolomide, a well-tolerated oral alkylating agent that permeates the blood brain barrier (BBB), is effective against malignant glioma and recurrent PCNSL. The gene for the deoxyribonucleic acid (DNA) repair enzyme O(6)-methylguanine-DNA methyltransferase (MGMT), which is closely related to cellular sensitivity to alkylating agents, is inactivated by promoter hypermethylation. We evaluated the results of temozolomide treatment and the methylation status of the promoter region of the MGMT gene in 17 patients (median age 68 years) with refractory or relapsed PCNSL. They were immunocompetent and had received initial treatment with HD-MTX (3.5 g/m(2)) with or without irradiation. All were treated with temozolomide 150-200 mg/m(2), for 5 days in the course of 28 days; treatment was continued until disease progression. We observed five complete remissions, five partial responses (PRs) with stable disease (SD), and seven with disease progression. Median overall survival after the temozolomide treatment was 6.7 months. One patient manifested grade 3 neutropenia and thrombocytopenia. Eleven tumor specimens were available for MGMT analysis. MGMT promoter methylation (mMGMT) in the tumor tissue was found in 4 (36.4%), the other seven harbored a non-methylated MGMT promoter (nmMGMT). There was no statistically significant difference in median overall survival between patients with mMGMT (11.1 months) and nmMGMT (6.7 months) (P = 0.63). Although some patients were elderly and had been heavily pre-treated, temozolomide resulted in a complete response (CR) in 29% and was well tolerated without any major toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.